SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-039896
Filing Date
2023-11-08
Accepted
2023-11-08 16:05:32
Documents
60
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 803581
2 ex31-1.htm EX-31.1 17683
3 ex31-2.htm EX-31.2 17704
4 ex32-1.htm EX-32.1 6619
5 ex32-2.htm EX-32.2 6519
  Complete submission text file 0001493152-23-039896.txt   4025805

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ltrn-20230930.xsd EX-101.SCH 31617
7 XBRL CALCULATION FILE ltrn-20230930_cal.xml EX-101.CAL 48271
8 XBRL DEFINITION FILE ltrn-20230930_def.xml EX-101.DEF 103009
9 XBRL LABEL FILE ltrn-20230930_lab.xml EX-101.LAB 256568
10 XBRL PRESENTATION FILE ltrn-20230930_pre.xml EX-101.PRE 204709
54 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 559855
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

IRS No.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39318 | Film No.: 231387765
SIC: 2834 Pharmaceutical Preparations